Parkinson Disease Symptom mild | Therapy Symptomatic Absent | Levodopa Absent | Antiparkinson Agents Absent | Dopamine Agonists To be stopped
Item
patients with idiopathic parkinson's disease and mild symptoms and not requiring symptomatic treatment with l-3,4-dihydroxyphenylalanine (l-dopa) or other anti-parkinson drugs. prior to entering the study, subjects may be on treatment with dopamine agonists provided that the treating neurologist agrees that the drugs can be stopped for at least three weeks prior to participating in the phenylbutyrate study and for the 4-week duration of the study.
boolean
C0030567 (UMLS CUI [1,1])
C0436343 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0023570 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0003405 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0178601 (UMLS CUI [5,1])
C1272691 (UMLS CUI [5,2])
Healthy Control Age Matched | Healthy Control Gender Matched
Item
age- and sex-matched normal control subjects will be recruited from spouses and the general population.
boolean
C2986479 (UMLS CUI [1,1])
C0001779 (UMLS CUI [1,2])
C0150103 (UMLS CUI [1,3])
C2986479 (UMLS CUI [2,1])
C0079399 (UMLS CUI [2,2])
C0150103 (UMLS CUI [2,3])
Study Subject All General health good
Item
all subjects will be in good general health.
boolean
C0681850 (UMLS CUI [1,1])
C0444868 (UMLS CUI [1,2])
C1277245 (UMLS CUI [1,3])
Hypertensive disease controlled with medications | Hypercholesterolemia controlled with medications
Item
candidates with hypertension or hypercholesterolemia controlled with medication are eligible.
boolean
C0020538 (UMLS CUI [1,1])
C0742801 (UMLS CUI [1,2])
C0020443 (UMLS CUI [2,1])
C0742801 (UMLS CUI [2,2])
Exclusion Criteria Patients | Exclusion Criteria Control Groups
Item
because of possible drug interactions and the unknown teratogenic risk of phenylbutyrate, exclusion criteria for both patients and controls include:
boolean
C0680251 (UMLS CUI [1,1])
C0030705 (UMLS CUI [1,2])
C0680251 (UMLS CUI [2,1])
C0009932 (UMLS CUI [2,2])
Pregnancy
Item
pregnant women
boolean
C0032961 (UMLS CUI [1])
Levodopa | Monoamine Oxidase Inhibitors | Catechol O-Methyltransferase Inhibitors | Histone deacetylase inhibitor | Prednisone | Adrenal Cortex Hormones
Item
current treatment with l-3,4-dihydroxyphenylalanine (l-dopa), monoamine oxidase (mao) inhibitors, catechol-o-methyl transferase (comt) inhibitors, histone deacetylase (hdac) inhibitors, prednisone or other corticosteroids
boolean
C0023570 (UMLS CUI [1])
C0026457 (UMLS CUI [2])
C2917201 (UMLS CUI [3])
C1512474 (UMLS CUI [4])
C0032952 (UMLS CUI [5])
C0001617 (UMLS CUI [6])
Probenecid
Item
probenecid
boolean
C0033209 (UMLS CUI [1])
Cardiopulmonary disease Severe | Congestive heart failure | Pulmonary Emphysema Requirement Supplemental oxygen
Item
severe cardiopulmonary disease such as congestive heart failure or emphysema requiring supplemental oxygen.
boolean
C0034072 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0018802 (UMLS CUI [2])
C0034067 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
C4534306 (UMLS CUI [3,3])
Kidney Disease Associated with Serum creatinine raised | Depressive disorder | Epilepsy | Cerebrovascular accident | Operation on brain | Dementia | Psychotic Disorders
Item
renal disease with serum creatinine greater than 2.5, history of depression in the prior year, epilepsy, stroke, prior brain surgery, dementia, or psychosis will also exclude candidates.
boolean
C0022658 (UMLS CUI [1,1])
C0332281 (UMLS CUI [1,2])
C0700225 (UMLS CUI [1,3])
C0011581 (UMLS CUI [2])
C0014544 (UMLS CUI [3])
C0038454 (UMLS CUI [4])
C0195775 (UMLS CUI [5])
C0497327 (UMLS CUI [6])
C0033975 (UMLS CUI [7])